HGS drug doesn't extend survival for lung cancer patients in study

03/18/2010 | Reuters

Cancer drug mapatumumab did not boost the efficacy of chemotherapy drugs paclitaxel and carboplatin in improving progression-free survival for patients with nonsmall-cell lung cancer during a midstage trial. Human Genome Sciences, maker of mapatumumab, tested the combination as a first-line therapy.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD